Ionizable Lipids

Discover ionizable lipids for lipid nanoparticle formulation and RNA delivery.

Avanti Research offers a portfolio of highly specialized ionizable lipids designed to support RNA delivery, gene therapy, and lipid nanoparticle (LNP) formulation. These synthetic cationic lipids exhibit pH-dependent charge behavior that promotes effective encapsulation, cellular uptake, and endosomal escape, which are essential characteristics in the development of nucleic acid therapeutics and mRNA-based vaccines.

Unlike permanently charged lipids, ionizable lipids offer a safer and more adjustable approach to intracellular delivery. Their ability to shift charge states based on pH enables low toxicity in systemic circulation and efficient membrane fusion inside acidic cellular compartments. Whether you're developing lipid nanoparticles for mRNA delivery, siRNA gene silencing, or genome editing tools like CRISPR/Cas9, Avanti Research's ionizable lipids for LNPs are purposefully built to meet the evolving demands of RNA-based drug development.

What are ionizable lipids, and why are they critical for RNA therapeutics?

Ionizable lipids are a subclass of synthetic lipids that gain a positive charge under acidic conditions, like the conditions of endosomes, but remain neutral at physiological pH. This property separates them from permanent cationic lipids, which are always charged and are often associated with increased cytotoxicity. Ionizable lipids are carefully engineered with specific pKa values, typically between 6.0 and 7.0, to optimize endosomal escape while minimizing unwanted effects and systemic toxicity.

This tunable behavior is critical in RNA delivery systems, particularly for mRNA vaccines, siRNA therapies, and CRISPR/Cas9-based gene editing. During LNP-mediated delivery, ionizable lipids facilitate high encapsulation efficiency and promote fusion with endosomal membranes to trigger the effective cytoplasmic release of the nucleic acid payload.

Their position as a cornerstone in RNA-based medicine is underscored by their role in enabling the delivery of COVID-19 mRNA vaccines, which has been widely studied and validated.

Explore applications for ionizable lipids in drug delivery and therapeutic development.

Avanti Research's ionizable and cationic lipids for RNA transfection are designed for versatility across a range of therapeutic platforms:

• mRNA vaccines for infectious disease prevention and cancer immunotherapy
• siRNA delivery for targeted gene silencing
• CRISPR/Cas9 delivery systems for in vivo and ex vivo genome editing
• Gene therapy and protein replacement strategies
• Ex vivo transfection for engineered cell therapies

These ionizable lipids for gene therapy are formulated for high payload encapsulation, membrane fusion, and controlled intracellular release, which is essential for building therapeutic lipid nanoparticles with predictable performance. When paired with Avanti Research high-purity PEG-lipids and helper lipids, your formulation pipeline gains the scalability and reproducibility necessary for clinical and commercial success.

Produce reliable results based on scientific trust and documentation.

Each ionizable lipid offered by Avanti Research is supported by:

• Certificate of Analysis (CoA)
• Material Safety Data Sheet (MSDS)
• Batch consistency and traceability
• Expert technical support for formulation

Our rigorous quality control ensures that researchers can rely on consistent performance in preclinical, translational, and clinical-stage development.

Explore our ionizable lipid portfolio!